Assertio: Funding, Investors & Team (Oct 2026)
Assertio is a specialty pharmaceutical company focused on developing and commercializing products to treat pain and other central nervous system conditions. The company was founded in 1995 and has established itself by developing and incorporating promising technology into differentiated therapeutic products, taking those products through clinical approval, and building a strong market presence. The company currently markets four FDA-approved products, Gralise (gabapentin) tablets for the management of Postherpetic Neuralgia (PHN), Cambia (diclofenac potassium for oral solution) for the acute treatment of migraine attacks with or without aura in adults 18 years of age or older, Zipsor (diclofenac potassium) liquid-filled capsules for relief of mild to moderate acute pain, and Lazanda (fentanyl) nasal spray CII for the management of breakthrough pain in cancer patients. See Important Safety Information for Gralise, Cambia, Zipsor, and Lazanda.
Assertio has raised $60.0M across 1 funding round on record, the most recent a Convertible Note of $60.0M announced in Aug 2022.
That round is above the $8.1M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Assertio Company Profile and Key Stats
Latest funding round on record: Aug 2022.
Assertio Funding Rounds
Assertio Founders and Leadership Team
Contact details for the Assertio team: 1 of 1 has an email address on file.
Start 14-day free trial →Assertio Funding Compared to Other Biotechnology Startups
Assertio's latest round of $60.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Assertio in Biotechnology and Lake Forest
Companies Similar to Assertio
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Circle Pharma is a biotechnology company in the initial stages of development that uses unique computational…
Evvy is for people with vaginas who want to be empowered with information about their microbiome. Their…
Assertio Funding FAQs
What does Assertio do?
Assertio is a specialty pharmaceutical company focused on developing and commercializing products to treat pain and other central nervous system conditions. The company was founded in 1995 and has established itself by developing and incorporating promising technology into differentiated therapeutic products, taking those products through clinical approval, and building a strong market presence. The company currently markets four FDA-approved products, Gralise (gabapentin) tablets for the management of Postherpetic Neuralgia (PHN), Cambia (diclofenac potassium for oral solution) for the acute treatment of migraine attacks with or without aura in adults 18 years of age or older, Zipsor (diclofenac potassium) liquid-filled capsules for relief of mild to moderate acute pain, and Lazanda (fentanyl) nasal spray CII for the management of breakthrough pain in cancer patients. See Important Safety Information for Gralise, Cambia, Zipsor, and Lazanda.
How much funding has Assertio raised?
Assertio has raised $60.0M across 1 round on record. The most recent is a Convertible Note of $60.0M announced in Aug 2022.
When did Assertio last raise funding?
Assertio's most recent funding round on record is a Convertible Note of $60.0M, announced in Aug 2022.
Who is the CEO of Assertio?
Arthur Higgins is listed as CEO at Assertio.
Where is Assertio headquartered?
Assertio is based in Lake Forest, Illinois, United States.
How many employees does Assertio have?
Assertio is in the 101-250 employee band.
How does Assertio's funding compare to other Biotechnology startups?
Assertio's latest round of $60.0M is above the $8.1M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Assertio Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Assertio is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.